131 related articles for article (PubMed ID: 24201549)
1. Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer.
Challapalli A; Barwick T; Tomasi G; O' Doherty M; Contractor K; Stewart S; Al-Nahhas A; Behan K; Coombes C; Aboagye EO; Mangar S
Nucl Med Commun; 2014 Jan; 35(1):20-9. PubMed ID: 24201549
[TBL] [Abstract][Full Text] [Related]
2. Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.
Contractor KB; Kenny LM; Stebbing J; Challapalli A; Al-Nahhas A; Palmieri C; Shousha S; Lewis JS; Hogben K; De Nguyen Q; Coombes RC; Aboagye EO
Nucl Med Commun; 2011 Nov; 32(11):997-1004. PubMed ID: 21862943
[TBL] [Abstract][Full Text] [Related]
3. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
4. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Scattoni V; Garcia Parra R; Briganti A; Gianolli L; Montorsi F; Messa C
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
[TBL] [Abstract][Full Text] [Related]
5. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
7. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.
Giovacchini G; Picchio M; Coradeschi E; Scattoni V; Bettinardi V; Cozzarini C; Freschi M; Fazio F; Messa C
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1065-73. PubMed ID: 18200444
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.
Fuccio C; Schiavina R; Castellucci P; Rubello D; Martorana G; Celli M; Malizia C; Profitos MB; Marzola MC; Pettinato V; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1985-9. PubMed ID: 21732105
[TBL] [Abstract][Full Text] [Related]
10. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
Ceci F; Castellucci P; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Ntreta M; Lodi F; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.
Mamede M; Ceci F; Castellucci P; Schiavina R; Fuccio C; Nanni C; Brunocilla E; Fantini L; Costa S; Ferretti A; Colletti PM; Rubello D; Fanti S
Clin Nucl Med; 2013 Sep; 38(9):e342-5. PubMed ID: 23797218
[TBL] [Abstract][Full Text] [Related]
13. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
[TBL] [Abstract][Full Text] [Related]
14. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
15. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer.
Rybalov M; Breeuwsma AJ; Leliveld AM; Pruim J; Dierckx RA; de Jong IJ
World J Urol; 2013 Apr; 31(2):319-23. PubMed ID: 22814886
[TBL] [Abstract][Full Text] [Related]
16. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
[TBL] [Abstract][Full Text] [Related]
17. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.
Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
World J Urol; 2015 Nov; 33(11):1749-52. PubMed ID: 25824540
[TBL] [Abstract][Full Text] [Related]
18. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy.
Breeuwsma AJ; Rybalov M; Leliveld AM; Pruim J; de Jong IJ
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):440-6. PubMed ID: 23069923
[TBL] [Abstract][Full Text] [Related]
19. Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?
Chondrogiannis S; Marzola MC; Ferretti A; Grassetto G; Maffione AM; Rampin L; Fanti S; Giammarile F; Rubello D
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1293-300. PubMed ID: 24566948
[TBL] [Abstract][Full Text] [Related]
20. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.
Krause BJ; Souvatzoglou M; Tuncel M; Herrmann K; Buck AK; Praus C; Schuster T; Geinitz H; Treiber U; Schwaiger M
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):18-23. PubMed ID: 17891394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
